News | Rubin Lab

Dr. Bishoy Faltas, MD, named AACR NextGen Star

March 3, 2017

Bishoy Faltas, MBBCh, Instructor in Medicine at Weill Cornell Medicine, was named a NextGen Star of the American Association for Cancer Research (AACR), an award that supporting the development and professional advancement of early-career scientists in cancer research. Dr. Faltas is currently focused on the molecular profiling of urothelial bladder carcinoma, a disease with the highest recurrence rate of any malignancy. He is working to...

Chemotherapy Drives Treatment Resistance in Bladder Cancer

October 17, 2016

Chemotherapy is indicated as the first line of treatment for advanced bladder cancer. New research by Weill Cornell Medicine and University of Trento scientists shows that while chemotherapy kills the most common type of bladder cancer, urothelial cancer, chemotherapy also shapes the genetic evolution of remaining urothelial cancer cell clones to become drug-resistant.

Treatments for urothelial cancer are limited. Within months of the initial treatment, usually with platinum-containing...

Gene Identified that Drives Aggressive Prostate Cancer

October 10, 2016

An overactive gene appears to cause some prostate cancers to transform from a typical tumor type to a much more aggressive form of the disease, according to new research at Weill Cornell Medicine.

Precision Cancer Test Validated for Clinical Usage

July 21, 2016

A powerful next-generation genome-sequencing test developed at Weill Cornell Medicine can detect mutations that guide precision cancer treatment with over 95 percent accuracy, according to new research. The scientists say their findings, published July 20 in NPJ Genomic Medicine, validate the test, called...

NIH awards $4M grant to advance precision medicine

July 8, 2016

Moving with what has been cited as unprecedented speed, the National Institutes of Health (NIH) has chosen a collaboration of four New York institutions -- Weill Cornell Medicine, NewYork-Presbyterian Hospital, Columbia University Hospital and NYC Health + Hospitals/Harlem -- to launch a landmark longitudinal research study as a part of President Barack Obama’s Precision Medicine Initiative (PMI).

The PMI Cohort Program aims to collect health, lifestyle and genetic information from 1...

Sequencing Reveals Underpinnings of Aggressive Prostate Cancer Subtype

February 9, 2016

A subset of treatment-resistant prostate cancer pathologically resembles small cell lung cancer rather than typical prostate cancer, Weill Cornell Medicine and University of Trento investigators discovered in a new study. The scientists say their findings may lead to more effective ways to diagnose and treat neuroendocrine prostate cancer. READ MORE

Researchers Validate Precision Medicine Approach Using New Whole Exome Sequencing Test

May 20, 2015

Weill Cornell Newsroom

Much of precision medicine and cancer care focuses on targeting the genomes of specific tumors or metastases. At Weill Cornell Medical College, a research team has now shown that a more global look at the body using next-generation sequencing can offer new insights — and targets — in patients with advanced, treatment-resistant disease. ...

Health: Make precision medicine work for cancer care

April 15, 2015

NATURE | COMMENT

To get targeted treatments to more cancer patients pair genomic data with clinical data, and make the information widely accessible, urges Mark A. Rubin. READ MORE

Big Data Key to Precision Medicine's Success

April 15, 2015

Weill Cornell Newsroom

Technological advances are enabling scientists to sequence the genomes of cancer tumors, revealing a detailed portrait of genetic mutations that drive these diseases. But genomic studies are only one piece of the puzzle that is precision medicine, a Weill Cornell Medical College researcher writes in Nature. In order to realize the promise of this field, there needs to be an increased focus on creating robust clinical...